JRSM > Volume 97, Number 5 > Pp. 226-229

This Article Abstract Full Text Full Text (PDF) Send a Quick Comment Alert me when this article is cited Alert me when Quick Comments are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Greene, O. Articles by Durrington, P. Search for Related Content PubMed PubMed Citation Social Bookmarking                      What's this?

Clinical management of children and young adults with heterozygous familial hypercholesterolaemia in the UK

Owen Greene BSc     Paul Durrington FRCP FMedSci  

University Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester M13 9WL, UK
E-mail: pdurrington{at}man.ac.uk

View larger version (20K): [in a new window]   Figure 1. Cumulative frequency distribution of the age at which physicians would introduce lipid-lowering medication in young people with heterozygous familial hypercholesterolaemia

 

View larger version (19K): [in a new window]   Figure 2. Cumulative frequency distribution of the level of serum cholesterol at which the physicians surveyed would introduce cholesterol-lowering medication in young people with heterozygous familial hypercholesterolaemia

 

View larger version (23K): [in a new window]   Figure 3. Age distribution of patients in whom physicians would choose to use a bile acid sequestrating agent (BAS) on its own or statin treatment alone or in combination with a BAS agent. A few physicians use fenofibrate alone in younger children (not shown). *Alone or in combination

 

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?